Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) SVP Sells 3,095 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) SVP Heather Raymon sold 3,095 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $27,885.95. Following the completion of the sale, the senior vice president owned 148,228 shares in the company, valued at approximately $1,335,534.28. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $8.55 on Wednesday. The stock has a market capitalization of $211.36 million, a P/E ratio of -2.42 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $14.53. The business has a 50-day moving average of $8.32 and a 200-day moving average of $5.65.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics during the third quarter worth approximately $41,000. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $53,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Wedbush lifted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Cantor Fitzgerald boosted their price target on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Needham & Company LLC increased their price objective on Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Artiva Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.